Tagrisso (osimertinib) has been approved by the US Food and Drug Administration (FDA) to treat a new subset of lung cancer ...

FDA has approved Tagrisso for the treatment of adult patients with locally advanced, unresectable NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based ...

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut ...

US FDA approves AstraZeneca’s Tagrisso for patients with unresectable, stage III EGFR-mutated lung cancer: Cambridge, UK Friday, September 27, 2024, 11:00 Hrs [IST] AstraZenecas ...

Trastuzumab deruxtecan is a HER2-directed antibody and topoisomerase inhibitor conjugate currently marketed under the brand name Enhertu (fam-trastuzumab deruxtecan-nxki) for the treatment of breast ...

Throughout September, the FDA approved drugs for the treatment of diseases including lung cancer, multiple myeloma, thyroid ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s TAGRISSO ® (osimertinib) has been approved in the US for the treatment of adult patients with unresectable, Stage III epidermal growth factor ...

Findings showed treatment with Rybrevant plus chemotherapy significantly reduced the risk of disease progression or death by 52% compared with chemotherapy.

Analysis of ctDNA in the MARIPOSA trial showed fewer EGFR alterations and MET amplifications after Rybrevant-Lazcluze treatment than after Tagrisso.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses the background and next steps of the LAURA study which evaluated osimertinib ...

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...